Top Banner
THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner Endowed Chair The Children’s Hospital of Philadelphia The Children’s Hospital of Philadelphia Professor of Surgery Professor of Surgery The University of Pennsylvania The University of Pennsylvania THE BORDERLINE LEFT VENTRICLE: Where to draw the line The Cardiac Center at The Children’s Hospital of Philadelphia NO DISCLOSURES
58

THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

Dec 31, 2015

Download

Documents

Ira Richardson
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

THOMAS L. SPRAY, MDTHOMAS L. SPRAY, MD

Chief, Cardiothoracic SurgeryChief, Cardiothoracic Surgery Alice Langdon Warner Endowed ChairAlice Langdon Warner Endowed Chair

The Children’s Hospital of PhiladelphiaThe Children’s Hospital of Philadelphia Professor of SurgeryProfessor of Surgery

The University of PennsylvaniaThe University of Pennsylvania

THE BORDERLINE LEFT VENTRICLE:

Where to draw the line

The Cardiac Center at The Children’s Hospital of Philadelphia NO DISCLOSURES

Page 2: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

ANATOMY OF VENTRICULAR HYPOPLASIA

LV Hypoplasia:• Aortic Stenosis• AS/ Mitral Stenosis• Coarctation of Aorta• TAPVR• IAA/VSD• TGA• Unbalanced AVSD

Page 3: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

CAN VENTRICULAR GROWTH BE STIMULATED AFTER BIRTH?

What Are The Signals For Ventricular Growth?

Positive: Flow (Volume, Shear Stress) Preload (Compliance) Negative: Afterload (Hypertrophy)

Page 4: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

CAN YOU VARY PRELOAD TO LV?

• Adjustable ASD• Leave Vertical Vein Open In

TAPVR:• Left-to-Right Shunt Volume Re-

Presented To LV• ? Capacitance of Functional LA

Page 5: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

LV “GROWTH” DEMONSTRATED WITH

REPAIR

Septal Shift, Volume Loading of LV, Volume Unloading of RV

Relief of Afterload on LV/RV

Page 6: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

LIMITATIONS TO BVR IN LV HYPOPLASIA:

“Fixed” Structural Lesions

• Endomyocardial Fibroelastosis• MV Stenosis• Straddling AV Valves• Anatomically Abnormal AV

Valves• Residual Outflow Obstructive

Lesions

Page 7: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

LV GROWTH IN CRITICAL AORTIC STENOSIS

• Criteria for BVR• Ross-Konno• Resection of EFE• Ross-Konno-MVR if MS• PHTN Late Complication

Page 8: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

Predictors of BVR in Critical AS:New “Rhodes” Score

12.16 (BSA) + 0.59 (aortic valve annulus z-score) +5.73 (LAR) – 7.02

Discriminant cutoff of 0.46 accurately predicts 91% of survivors and 80% events (death)

From: Colan, SD et al.JACC2006;47:1858-65From: Colan, SD et al.JACC2006;47:1858-65

Page 9: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Colan, SD et al.JACC2006;47:1858-65From: Colan, SD et al.JACC2006;47:1858-65

Predictors of BVR in Critical AS

Page 10: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Colan, SD et al.JACC2006;47:1858-65From: Colan, SD et al.JACC2006;47:1858-65

CHSS Formula for BVR vs. SVR in AS

Page 11: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

SURVIVAL BASED ON MANAGEMENT

From: Hickey, EJ, et al. JTCVS 2007;134:1429-37

Page 12: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

LV GROWTH IN “HLH COMPLEX” / CoA

• Repair Coarctation• ? ASD Restriction/ Closure• ? PA Band If VSD• When is BVR Failing And

Requires Conversion To SVR?

Page 13: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Serraf, A et al. JACC 1999;33:827-34From: Serraf, A et al. JACC 1999;33:827-34

HLHC Survival and Reoperation-Free SurvivalHLHC Survival and Reoperation-Free Survival

Page 14: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

LV GROWTH IN TAPVR

• Is The LV Ever Too Small?

• Should The Vertical Vein/ ASD Be Left Open?

Page 15: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

UNBALANCED AV CANAL

• 10% Of All Common Atrioventricular Canal• Right Dominant More Common Than Left

Dominant Forms• Right Dominant Associated With SubAS, CoA,

Arch Hypoplasia• High Morbidity And Mortality• Not Usually Associated With Down Syndrome • Few Published Reports

BACKGROUNDBACKGROUND

Page 16: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

• RV Volume > LV Volume In “Balanced” AV RV Volume > LV Volume In “Balanced” AV CanalCanal

• Degree Of Unbalance Of AV Valves May Not Degree Of Unbalance Of AV Valves May Not Correlate With Ventricular VolumesCorrelate With Ventricular Volumes

• Position Of Ventricular Septum May Be DisplacedPosition Of Ventricular Septum May Be Displaced• Patch Closure Of VSD May Increase LV VolumePatch Closure Of VSD May Increase LV Volume• Abnormal Geometry Of LV Outflow Tract And Abnormal Geometry Of LV Outflow Tract And

Ventricle Alters Accuracy Of MeasurementsVentricle Alters Accuracy Of Measurements

UNBALANCED AV CANAL

ERRORS IN MEASUREMENT OF VENTRICULAR VOLUME IN AVC

Page 17: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

UNBALANCED AV CANAL

• Considered To Be Higher Risk Lesion Than HLHS In Staged Reconstruction

• Atrioventricular Valve Regurgitation Is Common

• More Likely To Require Atrioventricular Valvuloplasty Or Replacement Than HLHS

SINGLE VENTRICLE REPAIRSINGLE VENTRICLE REPAIR

Page 18: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

UNBALANCED AV CANAL

• Antegrade Flow In Ascending AortaAntegrade Flow In Ascending Aorta• No PDA Or Only Left-To-Right No PDA Or Only Left-To-Right

Ductal FlowDuctal Flow• Restrictive Or No VSDRestrictive Or No VSD• AVVI > 0.27, Inflow Into Both AVVI > 0.27, Inflow Into Both

Ventricles SymmetricVentricles Symmetric• ““Potential” LV Volume > 15 ml/mPotential” LV Volume > 15 ml/m22

• Unbalance To The Left VentricleUnbalance To The Left Ventricle

FACTORS FAVORING TWO VENTRICLE REPAIR

Page 19: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

LV GROWTH IN UNBALANCED AVSD

• LV Inflow Primary Issue, Not LV Size

• Small MV, Especially With Small/Restrictive VSD or Restricted LV Inflow May Preclude Successful Repair Despite Reasonable LV Size (MR Through Cleft)

Page 20: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

UNBALANCED AV CANAL

IMPORTANT ANATOMIC/PHYSIOLOGIC IMPORTANT ANATOMIC/PHYSIOLOGIC VARIABLESVARIABLES

• Direction Of Ascending Aortic Flow• Ductal Shunt Direction• Relative Atrioventricular Valve Size• Atrioventricular Valve Anatomy/Fxn• Subaortic Stenosis • Arch Hypoplasia/Coarctation• Size Of VSD And Direction Of Shunt• Size Of LV/RVSize Of LV/RV

Page 21: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

The CHOP ApproachThe CHOP ApproachThe CHOP Approach

• Principle: If the inlet is sufficient the ventricle will be as well, so long as there is no other source of flow into the ventricle, i.e. VSD

• Derivative Principle: In the presence of a VSD, the LV cavity may appear seductively attractive for a 2V repair, but the inlet may be limiting!

• Principle: If the inlet is sufficient the ventricle will be as well, so long as there is no other source of flow into the ventricle, i.e. VSD

• Derivative Principle: In the presence of a VSD, the LV cavity may appear seductively attractive for a 2V repair, but the inlet may be limiting!

UNBALANCED AV CANAL

Page 22: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

STAGED LV RECRUITMENT

From: Emani, SM, et al. JACC 2012;60:1966-74

Page 23: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

ADVANTAGES OF LV “Rehabilitation”

• BVR eventually accomplished in 33% or more• LV size, function improves• Growth of left heart structures

DISADVANTAGES OF LV “Rehabilitation”

• AV still abnormal – AVR likely if previous intervention• MV still abnormal – MS/MR common, may eventually require MVR• LV diastolic function improved – long-term outcome unknown• Late exercise performance not known• PA pressures may not normalize• All risks of Norwood still present

Page 24: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

LV POST “Rehabilitation”

From: Emani, SM et al. JACC 2012;60:1966-74

Page 25: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

CHOP Selection Criteria For BVR (Survival 96%)

• MV Z-score >-3.7, Smallest MV dimension >5 mm

• No significant MS whether or not MV abnormal• Small PFO/ASD, modest gradient (<8 mm Hg.)• Mild LV hypoplasia (RV/LV 0.7-1.9)• Small or no VSD• No significant EFE• Mild-moderate arch gradient• Antegrade flow in arch

Page 26: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

Endocardial Fibroelastosis (EFE)• Major risk factor for poor outcome• Hard to diagnose• 3 Types: Grade 1 – Pap M involvement only

Grade 2 – Pap M and some endocardial involvement

Grade 3 – Extensive endocardial involvement

• Should all grades be addressed?• ? Effect of residual EFE• ? Results of scarring after resection

Page 27: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

WHEN IS SVR BETTER THAN BVR?

• After 1 Yr., SVR functional survival good for >20 yr.

• Functional results after BVR not well studied long-term

• Late decrease in compliance, elevated PVR and valve lesions may limit late options (Tx)

• Survival @ 20 yr. may be better with SVR, but ? @ 40 yr.

Page 28: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

“GOOD” BVR CANDIDATES

• Anatomically normal but hypoplastic left-sided intracardiac structures with antegrade arch flow

• AV stenosis with normally-functioning MV• No or Grade 1 EFE• MV Z-score >-3• AAVI > .27 with inflow into LV (CAVC)

Page 29: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

“POOR” BVR CANDIDATES

• LV hypoplasia plus unrestrictive VSD• Stenotic AV plus

abnormal/stenotic/hypoplastic MV• ? Grade 3 EFE with abnormal MV• ? Left-sided structures with Z-value <-4• AVVI >0.27 but with inflow directed into RV

(CAVC)

Page 30: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

SUMMARY

• Decisions About Ventricular Suitability For BV Repair Remain Difficult

• Despite Improved Measurement Techniques, Absolute Limits of LV/RV Hypoplasia Preventing BVR Remain Unclear

• Primary Issue Is Asessment Of Adequacy Of Ventricular Inflow and EFE

• Much Early LV/RV “Growth” After BVR Is Septal Repostioning From VSD Closure Or Decrease In RV Volume Load And Increase In LV Preload

Page 31: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

SUMMARY• Adjusting Preload To Stimulate Ventricular Growth May Be

Useful After Relief Of Obstruction Distally, but presumes adequate MV

• Overall Results With BVR In Patients With Borderline LV Not Much Different Than SV Reconstruction, Possibly With More Morbidity and Late Mortality

• Even When BVR Successful, Ventricles Can Have Abnormal Compliance

• AVSD Group Especially Difficult- MR May Limit Ability To Tolerate LV Loading

• Molecular Mechanisms Of LV Growth Remain To Be Clarified

Page 32: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.
Page 33: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.
Page 34: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Emani, SM et al. JACC 2012;60:1966-74

Page 35: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Emani, SM et al. JACC 2012;60:1966-74

Page 36: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Emani, SM et al. JACC 2012;60:1966-74

Page 37: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Emani, SM et al. JACC 2012;60:1966-74

Page 38: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Emani, SM et al. JACC 2012;60:1966-74

Page 39: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.
Page 40: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Emani, SM, et al. JTCVS 2009;138:1276-82

Page 41: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Emani, SM, et al. JTCVS 2009;138:1276-82

Page 42: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.
Page 43: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Cavigelli-Brunner, A., et al. Pediatr Cardiol 2012;33:506-12

Page 44: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Cavigelli-Brunner, A., et al. Pediatr Cardiol 2012;33:506-12

Page 45: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Cavigelli-Brunner, A., et al. Pediatr Cardiol 2012;33:506-12

Page 46: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.
Page 47: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Hickey, EJ, et al. JTCVS 2007;134:1429-37

Page 48: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Hickey, EJ, et al. JTCVS 2007;134:1429-37

Page 49: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Hickey, EJ, et al. JTCVS 2007;134:1429-37

Page 50: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Hickey, EJ, et al. JTCVS 2007;134:1429-37

Page 51: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Hickey, EJ, et al. JTCVS 2007;134:1429-37

Page 52: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Hickey, EJ, et al. JTCVS 2007;134:1429-37

Page 53: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Hickey, EJ, et al. JTCVS 2007;134:1429-37

Page 54: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.
Page 55: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Avitabile, CM, et al. Ann Thorac Surg 2015;99:877-83

Page 56: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.

From: Avitabile, CM, et al. Ann Thorac Surg 2015;99:877-83

Page 57: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.
Page 58: THOMAS L. SPRAY, MD THOMAS L. SPRAY, MD Chief, Cardiothoracic Surgery Chief, Cardiothoracic Surgery Alice Langdon Warner Endowed Chair Alice Langdon Warner.